-
Je něco špatně v tomto záznamu ?
Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate
J. Navrátilová, M. Karasová, M. Kohutková Lánová, L. Jiráková, Z. Budková, J. Pacherník, J. Šmarda, P. Beneš,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2000
PubMed Central
od 2000
Europe PubMed Central
od 2000 do 2020
ProQuest Central
od 2000-07-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2012-01-01
Medline Complete (EBSCOhost)
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-07-01
Wiley-Blackwell Open Access Titles
od 2000
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
28244639
DOI
10.1111/jcmm.13106
Knihovny.cz E-zdroje
- MeSH
- adenosintrifosfát metabolismus MeSH
- buněčné dýchání účinky léků MeSH
- down regulace účinky léků MeSH
- fibroblasty účinky léků metabolismus MeSH
- fosforylace účinky léků MeSH
- glukosa metabolismus MeSH
- inhibitory proteinkinas farmakologie MeSH
- kyselina mléčná biosyntéza MeSH
- lidé MeSH
- mitochondrie účinky léků metabolismus MeSH
- molybden farmakologie MeSH
- myši inbrední C57BL MeSH
- nádorové buněčné linie MeSH
- neuroblastom enzymologie metabolismus patologie MeSH
- neurony účinky léků metabolismus MeSH
- oxidativní fosforylace účinky léků MeSH
- protoonkogenní proteiny c-akt antagonisté a inhibitory metabolismus MeSH
- spotřeba kyslíku účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Neuroblastoma is the most common extracranial solid tumour of infancy. Pathological activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients. Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclinical trials as potential anti-cancer drugs. However, metabolic plasticity of cancer cells might undermine efficacy of this approach. In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase. It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells. The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids. Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate production in neuroblastoma cells, but not in normal fibroblasts and neuronal cells. Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells. Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities. The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025143
- 003
- CZ-PrNML
- 005
- 20180716114648.0
- 007
- ta
- 008
- 180709s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/jcmm.13106 $2 doi
- 035 __
- $a (PubMed)28244639
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Navrátilová, Jarmila $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Center for Biological and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
- 245 10
- $a Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate / $c J. Navrátilová, M. Karasová, M. Kohutková Lánová, L. Jiráková, Z. Budková, J. Pacherník, J. Šmarda, P. Beneš,
- 520 9_
- $a Neuroblastoma is the most common extracranial solid tumour of infancy. Pathological activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients. Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclinical trials as potential anti-cancer drugs. However, metabolic plasticity of cancer cells might undermine efficacy of this approach. In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase. It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells. The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids. Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate production in neuroblastoma cells, but not in normal fibroblasts and neuronal cells. Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells. Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities. The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.
- 650 _2
- $a adenosintrifosfát $x metabolismus $7 D000255
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a buněčné dýchání $x účinky léků $7 D019069
- 650 _2
- $a down regulace $x účinky léků $7 D015536
- 650 _2
- $a fibroblasty $x účinky léků $x metabolismus $7 D005347
- 650 _2
- $a glukosa $x metabolismus $7 D005947
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyselina mléčná $x biosyntéza $7 D019344
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a mitochondrie $x účinky léků $x metabolismus $7 D008928
- 650 _2
- $a molybden $x farmakologie $7 D008982
- 650 _2
- $a neuroblastom $x enzymologie $x metabolismus $x patologie $7 D009447
- 650 _2
- $a neurony $x účinky léků $x metabolismus $7 D009474
- 650 _2
- $a oxidativní fosforylace $x účinky léků $7 D010085
- 650 _2
- $a spotřeba kyslíku $x účinky léků $7 D010101
- 650 _2
- $a fosforylace $x účinky léků $7 D010766
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 _2
- $a protoonkogenní proteiny c-akt $x antagonisté a inhibitory $x metabolismus $7 D051057
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Karasová, Martina $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Kohutková Lánová, Martina $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Jiráková, Ludmila $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Budková, Zuzana $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Pacherník, Jiří $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Šmarda, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Beneš, Petr $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Center for Biological and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
- 773 0_
- $w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 21, č. 9 (2017), s. 1859-1869
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28244639 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180716114947 $b ABA008
- 999 __
- $a ok $b bmc $g 1317274 $s 1022064
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 21 $c 9 $d 1859-1869 $e 20170228 $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785
- LZP __
- $a Pubmed-20180709